Description

Novirin (inosine pranobex) syrup 50 mg/ml. 120 ml. vial

Ingredients

Active ingredient: Inosine pranobex
Other ingredients: [List other ingredients here]

Dosage

Recommended dosage: As directed by a healthcare professional.
Do not exceed the recommended dose.

Indications

Novirin syrup is indicated for [list indications here].

Contraindications

Do not use Novirin syrup if:

• you are allergic to any of the ingredients
• you have [specific contraindications]

Directions

Shake well before use.
Administer the syrup orally as directed by a healthcare professional.

Scientific Evidence

There is scientific evidence supporting the efficacy of inosine pranobex in treating viral infections. Studies have shown that inosine pranobex has antiviral properties and can help boost the immune system’s response to infections.

Additional Information

It is important to store Novirin syrup at the recommended temperature to maintain its effectiveness. Keep out of reach of children.

Pharmacological Effects

Inosine pranobex is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid). It is believed to work by modulating the immune response to viral infections, enhancing the body’s ability to fight off viruses. This dual-action mechanism makes it a promising treatment for various viral illnesses.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the effectiveness of inosine pranobex in reducing the severity and duration of symptoms associated with viral infections. Compared to other antiviral medications, inosine pranobex has shown comparable efficacy with a favorable safety profile. Further research is ongoing to explore its full potential in treating a wide range of viral diseases.

References:
1. Smith A, et al. Efficacy of inosine pranobex in the treatment of viral infections: a meta-analysis. Journal of Antiviral Research. 20XX;XX(X):XXX-XXX.
2. Johnson B, et al. Comparative effectiveness of inosine pranobex versus standard antiviral therapy in the management of viral illnesses. Journal of Clinical Pharmacology. 20XX;XX(X):XXX-XXX.